Integrative Analysis of Uveal Melanoma

  • Xiaolin XuEmail author
  • Xiao Zhang
Part of the Advances in Visual Science and Eye Diseases book series (AVSED, volume 3)


The difficulty of treatment of malignant tumors reflects the complexity of life sciences. The histo- and cytopathological changes from the previous histopathological diagnosis and the macroscopic imaging changes from a variety of imaging diagnosis have provided irreplaceable information for the diagnosis and prognosis evaluation of tumors. In recent years, with the development of molecular biology, the solutions for the difficult problems of oncology have been found out. The essence of tumor metastasis refers to the “invasive property” of cancer cells, which is the result of a series of genetic changes, fundamentally. Under what conditions the gene mutated to form the benign nevus, and under what conditions the gene mutated to form the invasive melanoma? From the view of dialectics, is there a possibility of mutual transformation? The ideal situation is to solve the macroscopic problems such as metastasis of malignant tumor through microscopic approaches, and then come back to the macroscopic level to achieve the prediction of tumor metastasis and the development of new drugs. Under the guidance of integrative medicine, we are looking forward to a promising future.


  1. 1.
    Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;109(12):2197–206.CrossRefPubMedGoogle Scholar
  2. 2.
    Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004;22(12):2438–44.CrossRefPubMedGoogle Scholar
  3. 3.
    Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol. 1978;62(6):420–5.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Damato B, Eleuteri A, Taktak AF, et al. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res. 2011;30(5):285–95.CrossRefPubMedGoogle Scholar
  5. 5.
    Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347(9010):1222–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Onken MD, Worley LA, Ehlers JP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Xu X, Wei WB, Li B, et al. Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese. PLoS One. 2014;9(10):e109699.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Infante JR, Papadopoulos KP, Bendell JC, et al. A phase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer. 2013;49:2077–85.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2020

Authors and Affiliations

  1. 1.Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical UniversityBeijingChina
  2. 2.Beijing Ophthalmology and Visual Sciences Key LaboratoryBeijingChina
  3. 3.Department of Ophthalmology Peiking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations